Assessment and prevalence of concomitant chemo-radiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma

Abstract

Background/aim Quantification of oral mucositis that progresses during concomitant chemo-radiotherapy (CCRT) is essential for its management. It is important to determine the methods that are simple, reliable and beneficial in foreseeing mucositis at earlier stages of treatment. Materials and methods A prospective study was conducted on 100 oral cancer patients receiving CCRT following the inclusion criteria. Patients were evaluated for mucositis i.e. erythema and ulcers by using the World Health Organization (WHO) scale and the oral mucositis assessment scale (OMAS), whereas mature and immature cells were identified by exfoliative cytology. Clinical examination and procedure of oral cavity were performed before, on days 5, 17, and at the end of treatment. Results Oral mucositis was observed in all oral squamous cell carcinoma (OSCC) patients receiving CCRT on different days with noteworthy increase from day 5 of CCRT to the end of treatment. For OMAS grading related to ulceration and erythema, Grade 1 (7.2%; 34%) was most commonly seen on the 5th day of CCRT, Grade 2 (29%; 19%) and Grade 3 (19%) were most frequently seen at the 17th day and end of CCRT, accordingly. With respect to WHO scale grades 1 and 2 (18.3%; 21.5%) was most frequently observed at the 17th day of CCRT, whereas grades 3 and 4 (12.5%; 2%) was noted at the end of CCRT. There was statistically significant increase in the percentage of immature cells at the end of CCRT (99%). A significant association (P < 0.0000) was observed among the days of smear and maturation stages of epithelial cells as well as among WHO mucositis grading, OMAS and types of epithelial cells, respectively. Conclusion According to the findings of the study, oral mucositis grade is directly proportional to the progressing days of CCRT. Oral mucositis is frequently related to adverse clinical outcomes, affecting the patient’s quality of life. It is essential to develop methods that can be employed for the assessment of CCRT associated oral mucositis.

Nazofarengeal Karsinom Tedavisinde Yoğunluk Ayarlı Radyoterapi ile Kombine Kemoterapinin Akut Yan Etkileri

“…18 In a study by Igor et al, oral mucositis was observed in men with a rate of 78.2%. 19 In our study, the incidence rate of grade III mucositis in men was 53%. Luo et al found the most common toxicity with chemoradiotherapy in NPC were grade III or IV oral mucositis (40%), pharyngo-esophagitis (12%), leukopenia (29.6%) and neutropenia (26.4%).…”

Comparative evaluation of oral mucositis in oral cancer patients undergoing 3-dimensional conformal radiation therapy and intensity modulated radiation therapy with or without chemotherapy

“…On the contrary, Minhas et al . (2021)[ 15 ] reported tongue to be the most predominant site for the occurrence of OSCC.…”

Knowledge, Attitude, and Skills of Oral Health Care Professionals towards Cancer Treatment-induced Oral Mucositis.

“…But in addition to systemic symptoms, patients frequently have oral health problems such as candidiasis, gingivitis, ulcers, xerostomia, accumulation of plaque, dysphagia, and dysgeusia. These oral health issues are very likely to have a signi cant negative impact on quality of life, both psychologically in the form of anxiety, and sadness and functionally in the form of di culty in speaking, and masticating food [10,11].…”